Figure 4.

Distribution of the number of comorbidities in nirmatrelvir/ritonavir (Paxlovid^TM) recipients, Canada^a,b, 2022 (n=59,452)

^a Based on data from six reporting jurisdictions

^b “Comorbidities” refers to the following conditions: obesity (BMI≥30), chronic kidney disease, diabetes, heart disease, hypertension, congestive heart failure, chronic respiratory disease including cystic fibrosis, cerebral palsy, intellectual disability, sickle cell disease, moderate or severe kidney disease (eGFR<60 mL/min), and moderate or severe liver disease (e.g. Child Pugh, Class B or C cirrhosis)